These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38847351)

  • 21. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.
    Cellamare M; Milstein M; Ventz S; Baudin E; Trippa L; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):8-12. PubMed ID: 28240566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Balanced covariates with response adaptive randomization.
    Saville BR; Berry SM
    Pharm Stat; 2017 May; 16(3):210-217. PubMed ID: 28261972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using Bayesian hierarchical models for controlled post hoc subgroup analysis of clinical trials: application to smoking cessation treatment in American Indians and Alaska Natives.
    Shergina E; Richter KP; Makosky Daley C; Faseru B; Choi WS; Gajewski BJ
    J Biopharm Stat; 2024 Jul; 34(4):513-525. PubMed ID: 37417836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of response adaptive randomization features in multiarm clinical trials with control.
    Viele K; Saville BR; McGlothlin A; Broglio K
    Pharm Stat; 2020 Sep; 19(5):602-612. PubMed ID: 32198968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time-trend impact on treatment estimation in two-arm clinical trials with a binary outcome and Bayesian response adaptive randomization.
    Jiang Y; Zhao W; Durkalski-Mauldin V
    J Biopharm Stat; 2020; 30(1):69-88. PubMed ID: 31017843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
    Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
    Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familywise error control in multi-armed response-adaptive trials.
    Robertson DS; Wason JMS
    Biometrics; 2019 Sep; 75(3):885-894. PubMed ID: 30714095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling.
    Gajewski BJ; Berry SM; Barsan WG; Silbergleit R; Meurer WJ; Martin R; Rockswold GL
    Pharm Stat; 2016 Sep; 15(5):396-404. PubMed ID: 27306921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study.
    Connor JT; Luce BR; Broglio KR; Ishak KJ; Mullins CD; Vanness DJ; Fleurence R; Saunders E; Davis BR
    Clin Trials; 2013 Oct; 10(5):807-27. PubMed ID: 23983160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.
    Thall P; Fox P; Wathen J
    Ann Oncol; 2015 Aug; 26(8):1621-8. PubMed ID: 25979922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Block response-adaptive randomization in clinical trials with binary endpoints.
    Magirr D
    Pharm Stat; 2011; 10(4):341-6. PubMed ID: 22328326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can response-adaptive randomization increase participation in acute stroke trials?
    Tehranisa JS; Meurer WJ
    Stroke; 2014 Jul; 45(7):2131-3. PubMed ID: 24916909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A practical response adaptive block randomization (RABR) design with analytic type I error protection.
    Zhan T; Cui L; Geng Z; Zhang L; Gu Y; Chan ISF
    Stat Med; 2021 Oct; 40(23):4947-4960. PubMed ID: 34111902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptive trial designs: a review of barriers and opportunities.
    Kairalla JA; Coffey CS; Thomann MA; Muller KE
    Trials; 2012 Aug; 13():145. PubMed ID: 22917111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.